Fmr LLC Buys 12,729 Shares of Xencor, Inc. (NASDAQ:XNCR)

Fmr LLC grew its stake in Xencor, Inc. (NASDAQ:XNCR) by 315.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,764 shares of the biopharmaceutical company’s stock after acquiring an additional 12,729 shares during the quarter. Fmr LLC’s holdings in Xencor were worth $337,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in XNCR. Primecap Management Co. CA grew its stake in Xencor by 0.3% in the second quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock valued at $172,570,000 after purchasing an additional 25,495 shares during the last quarter. Logos Global Management LP lifted its position in shares of Xencor by 130.8% during the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $28,395,000 after buying an additional 850,000 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Xencor by 6.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock valued at $27,628,000 after buying an additional 87,979 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of Xencor by 52.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,261,789 shares of the biopharmaceutical company’s stock worth $23,886,000 after buying an additional 436,389 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Xencor by 7.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 626,988 shares of the biopharmaceutical company’s stock worth $12,609,000 after acquiring an additional 40,788 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on XNCR shares. BMO Capital Markets restated an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. Wedbush reissued an “outperform” rating and issued a $38.00 price objective on shares of Xencor in a research report on Thursday, November 7th. Wells Fargo & Company started coverage on Xencor in a research note on Thursday, December 12th. They set an “overweight” rating and a $37.00 target price on the stock. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and increased their price target for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. Finally, JPMorgan Chase & Co. boosted their price target on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $36.56.

Insider Buying and Selling at Xencor

In other Xencor news, CEO Bassil I. Dahiyat sold 49,278 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $24.07, for a total transaction of $1,186,121.46. Following the completion of the transaction, the chief executive officer now directly owns 352,615 shares in the company, valued at approximately $8,487,443.05. This represents a 12.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of Xencor stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares in the company, valued at approximately $4,698,441.92. This trade represents a 25.55 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 136,050 shares of company stock worth $3,277,609. Insiders own 5.23% of the company’s stock.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $24.01 on Friday. Xencor, Inc. has a 52 week low of $15.31 and a 52 week high of $27.24. The business’s 50 day moving average price is $23.40 and its 200 day moving average price is $20.70. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.68 billion, a P/E ratio of -7.50 and a beta of 0.69.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.27. The business had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business’s quarterly revenue was down 81.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.40) EPS. On average, sell-side analysts expect that Xencor, Inc. will post -3.71 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.